首页> 外文学位 >Regenerative Medicine Innovation in Emerging Economies: A Case Study Comparison of China, Brazil and India.
【24h】

Regenerative Medicine Innovation in Emerging Economies: A Case Study Comparison of China, Brazil and India.

机译:新兴经济体中的再生医学创新:中国,巴西和印度的案例比较。

获取原文
获取原文并翻译 | 示例

摘要

Regenerative medicine (RM) has the potential to develop new treatments for chronic disease and injury that are desperately needed in developing countries. Several emerging economies are actively participating in RM, producing new knowledge and initiating clinical trials. This thesis presents case studies of RM in China and Brazil and a comparative analysis of RM across Brazil, China and India. I aim to better understand the state of RM, how it has developed and what is needed for RM innovation to succeed within these countries. Case studies were conducted using face-to-face in-depth semi-structured interviews with RM experts from different areas including research institutes, hospitals, firms, educational institutes, government, policy agencies, and bioethics groups. Interviews were analysed using thematic analysis and triangulated with the analysis of research articles, government reports, laws and other primary and grey literature. China is now the 5th most prolific publisher on stem cells in the world. Chinese RM benefits from permissive regulations and the expertise of Chinese returnees that have trained abroad, but the field's reputation is challenged by a weak regulatory system and the clinical availability of untested stem cell therapies. Brazil has created a small but strong RM program, but needs to address challenges to the field including inconsistent funding, slow importation of materials, and weak linkages between stake-holders. Comparative analysis of the three countries identifies several common elements that support RM, including linkages between stake-holders, government support, infrastructure, human resources, and good governance. RM capacity is clustered in large urban centres, which could exacerbate socio-economic and health disparities unless measures are taken to ensure equitable distribution of benefits. RM does not adhere to classical views of southern innovation, suggesting that new models are needed to describe innovation in emerging technologies, where countries are keeping up instead of catching up.
机译:再生医学(RM)有潜力为发展中国家急需的慢性疾病和损伤开发新的治疗方法。几个新兴经济体正在积极参与RM,产生新知识并开始临床试验。本文介绍了中国和巴西的RM案例研究,以及巴西,中国和印度的RM对比分析。我的目的是更好地了解RM的现状,发展状况以及RM创新在这些国家/地区取得成功所需的条件。案例研究是通过与来自研究机构,医院,企业,教育机构,政府,政策机构和生物伦理学团体等不同领域的RM专家进行面对面的深入半结构化访谈进行的。使用主题分析法对访谈进行了分析,并对研究文章,政府报告,法律以及其他主要和灰色文献进行了分析。中国现在是世界上干细胞产量最高的第五位。中国的RM得益于宽松的法规和在海外接受培训的中国海归的专业知识,但监管体系薄弱以及未经测试的干细胞疗法的临床可用性,给该领域的声誉带来了挑战。巴西制定了一个规模虽小但功能强大的风险管理计划,但需要解决该领域的挑战,包括资金不一致,材料进口缓慢以及利益相关方之间的联系薄弱。对这三个国家的比较分析确定了支持RM的几个共同要素,包括利益相关者,政府支持,基础设施,人力资源和善政之间的联系。风险管理能力集中在大型城市中心,除非采取措施确保公平分配利益,否则这可能加剧社会经济和健康差距。 RM不遵循有关南方创新的经典观点,这表明需要新的模型来描述新兴技术的创新,而新兴技术在这些国家正在跟上而不是赶上。

著录项

  • 作者

    McMahon, Dominique S.;

  • 作者单位

    University of Toronto (Canada).;

  • 授予单位 University of Toronto (Canada).;
  • 学科 Health Sciences Public Health.;Health Sciences Health Care Management.;Political Science General.
  • 学位 Ph.D.
  • 年度 2011
  • 页码 303 p.
  • 总页数 303
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:44:14

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号